The Global Animal Vaccines Market Continues To Grow Owing To the High Launch of Novel Treatment Options for Animals


Animal Vaccines Market, by Product Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, and Recombinant Vaccines), by Application (Companion Animal, Livestock Animal, Poultry, and Aquaculture), by Distribution Channel (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028.

Veterinary vaccines play a critical role in preventing disease and improving animal health. They are also important tools to protect human health. The development and use of veterinary vaccines have resulted in an increase in the amount of safe and healthy food that is available for human consumption. Animals can be vaccinated with inactivated and live bacterial and viral vaccines. Inactivated viral vaccines are used to reduce the virulence of the infection. However, they are often not effective against the prevailing strains in the field. It is important to develop new and improved-inactivated viral vaccines to help overcome this challenge. Many attenuated bacterial strains have been developed for decades and are used to prevent bacterial diseases in veterinary medicine. Recent advances in the development of attenuated vaccines are allowing for greater efficacy of these products. These include the introduction of improved adjuvanted formulations and the removal of maternal antibodies from young animals.

The global Animal Vaccines Market is estimated to be valued at US$ 7,119.7 Mn in 2021, and is expected to exhibit a CAGR of 6.6% over the forecast period (2021-2028).

Competitive Landscape:

Major players operating in the global animal vaccines market include Biogénesis Bagó, Hester Biosciences Limited, NEOGEN CORPORATION, Ceva, Zoetis, MSD Animal Health, Virbac, Boehringer Ingelheim International GmbH, HIPRA, and Elanco.

Key Market Drivers:

Increasing developments in the global animal vaccines market are expected to augment the growth of the market. For instance, in September 2020, Hester Biosciences Limited developed the Brucella vaccine, which will ensure lifelong immunity in calf-hood. The use of a variety of different microbial derivatives, including saponins, liposomes, and aluminum salts is being tested. Some of these are already licensed and marketed for use in dogs and pigs, while others are still in development. Moreover, the high adoption of pets and expansion of animal shelters are estimated to enhance the growth of the global market.

Covid-19 Impact Analysis

During the COVID-19 pandemic, there have been several developments in the global market. For instance, in February 2020, MSD Animal Health (Merck Animal Health) introduced Nasalgen, which is an intranasal inoculation product. Nasalgen will be protecting dairy and beef cattle from several pneumonia-causing viral pathogens.

Key Takeaways

· North America is expected to dominate the growth of the global market, owing to the high developments by key players in the region. For instance, in February 2020, the United States Food and Drug Administration gave approval for Zoetis's Simparica, which is a chewable tick and flea medicine for dogs.

· The Asia Pacific is estimated to witness high growth in the global market, owing to the launch of new treatments in the region. For instance, in November 2020, HIPRA Indonesia virtually launched GUMBOHATCH's new generation Infectious Bursal Disease immune complex immunization product meant for broiler chickens.


Comments

Popular posts from this blog

Refinery Catalysts are Important Components of a Petroleum Refinery

Wearable Injector are Devices Which Adhere to the Body and Help in Administering Drug to the Patient

Global Flocculant And Coagulant Market Is Estimated To Witness High Growth Owing To Increasing Demand For Water Treatment Applications